Get the Stockscreener App
3.4899
11.86%
0.3699
Medicus Pharma Ltd stock is traded at $3.4899, with a volume of 31,827.
It is up +11.86% in the last 24 hours and down -54.11% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$3.12
Open:
$3.09
24h Volume:
31,827
Relative Volume:
0.29
Market Cap:
$5.01M
Revenue:
Net Income/Loss:
$-28.53M
P/E Ratio:
-1.9601
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-31.50%
1M Performance:
-54.11%
6M Performance:
-76.90%
1Y Performance:
-96.95%
1-Day Range:
$3.00
$3.49
1-Week Range:
$2.9214
$4.74
52-Week Range:
$1.865
$139.00
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
3.4899 | 5.01M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,260.90 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.72 | 613.84B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
286.48 | 506.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.26 | 365.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.93 | 286.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why - Benzinga
Medicus Pharma to implement 50-for-1 share consolidation to meet Nasdaq minimum bid - TradingView
Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12 - StreetInsider
Medicus Pharma Ltd. Warrant (MDCXW) Holds Flat at $0.35 Inside a Narrow Trading BandMACD Signal Stocks - https://www.dars.gov.et/
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Medicus Pharma ends standby equity purchase agreement with Yorkville - Investing.com
How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan
MDCX 8-K FilingsMedicus Pharma Ltd. SEC 8-K - Stock Titan
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com UK
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Yahoo Finance
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Canada
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com UK
FDA authorizes the next study of a skin cancer patch - Stock Titan
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - stocktitan.net
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - stocktitan.net
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - stocktitan.net
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Yahoo Finance
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):